Naproxen sodium was administered to cynomolgus monkeys (Macaca fascicularis) by oral gavage at daily doses of 44, 88, or 176 mg/kg for 2 wk (2 monkeys/gender) or of 44 mg/kg for 13 wk (4 monkeys/gender). Body weight loss occurred in at least one monkey in all naproxen sodium-dosed groups in the 2-wk (up to 16% loss) and 13-wk (up to 22% loss) studies. Increases in plasma naproxen concentrations were dose proportional between 44 and 88 mg/kg but were less than dose proportional between 88 and 176 mg/kg. Up to 2-fold increases in creatinine and/or serum urea nitrogen values as well as higher renal weights occurred in monkeys receiving 176 mg/kg for 2 wk or 44 mg/kg for 13 wk. Microscopically, renal changes were observed in all naproxen sodium-dosed groups. Renal findings after 2 wk of exposure included increased interstitial ground substance, tubular dilatation, and tubulointerstitial nephritis; in the 13-wk study, cortical tubular atrophy and interstitial fibrosis were also observed. These studies identify the kidney as the target organ of naproxen sodium in cynomolgus monkeys.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are aspirin-like drugs that are widely used in humans for their beneficial anti-inflammatory, analgesic, and antipyretic effects (30, 39) . NSAID administration has also been associated with a variety of adverse effects in humans and laboratory animals, including adverse renal effects (4, 6, 20, 30, 36, 39) . Although the classification schemes of NSAID-related renal effects in humans vary somewhat between authors, a number of syndromes have generally been described. These include acute ischemic renal insufficiency, which can be associated with azotemia and tubular necrosis; interstitial or tubulointerstitial nephritis, which can be associated with azotemia and/or proteinuria; abnormalities in sodium, potassium, and water metabolism ; and possibly papillary necrosis (2, 13, 14, 17, 39, 42) . Papillary necrosis and secondary chronic nephritis, termed analgesic nephropathy, have been more frequently associated with consumption of other aspirin-like drugs that lack significant anti-inflammatory activity, such as phenacetin (4, 9, 17, 30) . While adverse renal effects related to NSAIDs and other aspirin-like drugs are considered uncommon in humans, there is concern that these effects may occur more frequently than is currently recognized (27, 39) , and it was recently recommended that prolonged, regular use of NSAIDs should be avoided (17) . Administration of NSAIDs to laboratory animals has not proven to be a good model of NSAID-related renal disease, because the spectrum of disease observed in humans is not seen in laboratory animals, and these animals often develop significant extrarenal toxicity (4, 6, 27) .
Naproxen is a commonly used NSAID that is available either as the free acid (hereafter referred to as naproxen) or as the sodium salt (hereafter referred to as naproxen sodium) (52) . Pharmacokinetic differences between the formulations are restricted to the slightly earlier and higher plasma concentrations achieved with naproxen sodium, which result in a slightly faster onset of action; in other respects the 2 formulations are pharmacokinetically, pharmacologically, and therapeutically equivalent at comparable doses (38, 48, 52) . Naproxen and naproxen sodium are generally considered to be efficacious, safe, and well tolerated in humans, although renal and gastrointestinal side effects similar to those observed with other NSAIDs are occasionally seen (15, 18, 52) .
As part of a program to identify drugs that might be suitable for use in combination with proprietary compounds, the toxicity of orally administered naproxen sodium was evaluated in cynomolgus monkeys (Macaca fascicularis) in a 2-wk range-finding study and in a 13wk toxicology study. To our knowledge, studies evaluating the toxicity of naproxen or naproxen sodium had not previously been conducted in this species.
MATERIALS AND METHODS
Animals and Husbandry. Juvenile to young adult cynomolgus monkeys (M. fascicularis), considered to be healthy on the basis of pretest physical examinations (both studies), a routine battery of hematologic and serum chemistry evaluations (both studies), and urinalysis and urine chemistry evaluations (13-wk study only), were used. Monkeys were assigned to groups on a stratified random basis according to gender and body weight. Groups of 2 monkeys per gender, weighing 4.5 to 5.6 kg (males) or 3.0 to 3.5 kg (females), were used in the 2wk study. Groups of 4 monkeys per gender, weighing 2.0 to 3.4 kg (males) or 1.9 to 2.8 kg (females), were used in the 13-wk study. Monkeys were housed individually in stainless steel cages in environmentally controlled rooms (temperature 72 ± 4°F, relative humidity 50 ± 20%, 12-hr light/dark photoperiod), were offered Agway/ N.I.H. Formula Certified 46 Diet@ supplemented with Prima-Treats&copy; (Bioservg, Frenchtown, NJ) on a daily basis, and were provided tap water ad libitum. The studies were conducted in a facility accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC) and in compliance with the NIH Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act.
Test Article and Administration. Naproxen sodium [(S)-6-methoxy-a-methyl-2-naphthaleneacetic acid, sodium salt] (Alfa Chemicals Italiana, Milano, Italy) was dissolved in 5 ml of 0.4% methylcellulose (Schering-Plough Products, Inc., Manati, Puerto Rico) and administered by oral gavage at daily doses of 44, 88, or 176 mg/kg (equivalent to 40, 80, or 160 mg/kg of naproxen, respectively) for 14 or 15 days (2-wk study) or at a daily dose of 44 mg/kg for 13 wk. Naproxen sodium concentrations in the dosing solutions were 8.8, 17.6, and 35.2 mg/ml for the 44, 88, or 176 mg/kg dose groups, respectively. Analysis of dosing solutions used during weeks 1 and 2 (2-wk study) and during weeks 1, 4, and 11 1 (13-wk study) showed that naproxen sodium concentrations in the dosing solutions were within 10% of the intended concentrations at all dose levels. Control monkeys received 5 ml of the 0.4% methylcellulose vehicle.
Clinical Examinations. Clinical observations and es-
timates of food consumption were made daily, and body weights were recorded weekly. General veterinary examinations and blood sampling for hematology, coagulation assays, and serum chemistry parameters were conducted pretest and during week 2 (2-wk study) or pretest and during weeks 4 and 13 (13-wk study). Urinalysis and urine chemistry parameters were evaluated pretest and during weeks 4 and 13 in the 13-wk study but were not evaluated in the 2-wk study. Clinical pathology data were evaluated for alterations from pretest values and were compared with concurrent and historical control ranges.
Historical control data were used because of the small number of animals in each group. (Historical data were collected from pretest values that were determined at our facility in Lafayette, New Jersey, using identical instrumentation/methodology as that used in the present studies. Only values obtained from apparently healthy mon-keys were used. The low and high historical control values represent a 95% range of the data set.) In the 13-wk study, body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram data were collected from all monkeys during weeks 5 and 12.
Plasma Drug Analysis. Plasma concentrations of naproxen were determined in heparinized blood samples obtained, by femoral venipuncture, from all monkeys during week 2 at 1, 6, and 24 hr after dosing in the 2wk study. In the 13-wk study, samples were collected at 2, 6, and 24 hr after dosing on days 1 (week 1 ), 34 (week 5), and 71 (week 11). The 2-hr time point was selected in the 13-wk study based on the need to collect data at this time point from other groups in the study that received other compounds (data not shown). Plasma samples were analyzed for naproxen concentrations using a validated high-performance liquid chromatographic (HPLC) method with internal standardization. An aliquot (100 u-l) of each plasma sample was spiked with the internal standard (indomethacin) and extracted with an organic solvent. Following evaporation of the organic layer, the residue was reconstituted in mobile phase (water :acetonitrile, pH 3.0) and analyzed on an HPLC system utilizing a C-18 column and an ultraviolet detector set at a wavelength of 230 nm. The recovery of naproxen from monkey plasma ranged from approximately 95 to 77% between 0.60 and 80 ~,g/ml. The method was linear and reproducible from 0.20 to 100 pLg/ml naproxen, with a limit of quantitation of 0.20 pLg/ml. The area under the plasma concentration-time curve from 0 to 24 hr after dosing (AUC [0-24 hr]) was calculated using the linear trapezoidal method. For samples collected after day 1, the 24-hr value was used as the 0 hr concentration for calculation of the AUC, assuming that steady state had been reached.
Pathology. Following an overnight fast, monkeys were anesthetized with sodium pentobarbital, exsanguinated, and a necropsy was conducted. Absolute and relative weights of the liver, kidneys (right and left combined), and spleen were recorded in the 2-wk study, whereas weights from all major organs were collected in the 13-wk study. Changes in organ weights were considered related to naproxen sodium administration only if both the absolute and relative weights were higher or lower than weight-matched concurrent and historical control weights. Historical control data were used because of the small number of animals in each group. (Historical data were collected from control cynomolgus monkeys necropsied and weighed at our facility in Lafayette, New Jersey, from 1982 to 1996. Males and females were stratified into 6 or 4 groups, respectively, based on body weight, in order to provide comparisons based on body weight. The low and high values represent a 95% range of the data set.) In the 2-wk study, the esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, kidneys, and liver were fixed by immersion in 10% neutral-buffered formalin, and all collected tissues were routinely processed, sectioned at 6 [Lm, and stained with hematoxylin and eosin (H&E).
In the 13-wk study, all major organs were fixed by immersion in 10% neutral-buffered formalin, but only H&E-stained slides of the kidney were made. To further clarify the nature of the renal interstitial changes, Masson's trichrome and Movat's pentachrome stains were done on all renal sections from monkeys in the 2-wk study. In the 13-wk study, periodic acid-Schiff (PAS), Masson's trichrome, and Movat's pentachrome stains were performed on renal sections from 1 control and from 2 naproxen sodium-dosed monkeys of each gender.
RESULTS

In-Life Observations
All monkeys in both studies survived until the scheduled necropsies. Food consumption was reduced in monkeys receiving 88 or 176 mg/kg naproxen sodium in the 2-wk study (data not shown). The reduced food consumption increased in incidence and severity between weeks 1 and 2. Food consumption was similar to that of controls in the 13-wk study. Compared with controls, body weight losses were observed in both studies (Fig.  1 ). In the 2-wk study, controls had slight body weight gains or losses of less than 3.5% (a typical finding in 2wk studies). Weight losses greater than those seen in controls occurred in 1/2 females receiving 44 mg/kg/day, in 1/2 males and 2/2 females receiving 88 mg/kg/day, and in 2/2 males and 2/2 females receiving 176 mg/kg/day. Weight loss in the 2-wk study was dose related, and females were typically more severely affected, with up to a 16% loss observed in females receiving 176 mg/kg. In the 13-wk study, control monkeys maintained their body weight or had slight weight gains. In contrast, 3/4 males and 3/4 females receiving 44 mg/kg of naproxen sodium for 13 wk had body weight loss; the maximal weight loss observed was 22%. Most of the weight loss in the 13wk study occurred over the last several weeks of dosing (data not shown), and this weight loss was greater than B) Data from 13-wk study. Monkeys received naproxen sodium at a daily dose of 44 mg/kg. Samples were collected after dosing on day 1 (A), day 34 (0), and day 71 (8) . Concentrations at the 0-hr time point for days 34 and 71 are based on the 24-hr concentrations for days 34 and 71, respectively. Error bars represent the upper and lower ranges of plasma concentrations observed at that time point during any of the day 1, 34, or 71 samplings. that observed in the 2-wk study at the 44 mg/kg dose.
There were no other naproxen sodium-related in-life findings in either the 2or 13-wk studies.
Plasma Drug Analysis
Naproxen plasma concentration data are shown in Fig.  2 and in Table I . Naproxen was rapidly absorbed following oral administration in both studies. Maximum plasma concentrations occurred at 1 or 2 hr postdose, the earliest time points examined in the 2-and 13-wk studies, respectively. Based on these limited samples, the time to peak plasma concentration (Tmax) of naproxen sodium appeared to be earlier than 6 hr, as the plasma concentrations at 1or 2-hr time points were much higher than those at the 6-hr time point in both studies. Naproxen concentrations were low but still quantifiable at 24 hr postdose in all naproxen sodium-dosed groups in both studies. Dose-proportional increases in plasma concentrations were observed between 44 and 88 mg/kg; between 88 and 176 mg/kg, the increases were dose related but less than dose proportional. There was no evidence of accumulation in the 13-wk study, as naproxen plasma concentrations were similar at the day 1, 34, and 71 time points. No gender-related differences in naproxen exposure were observed in either study (data not shown).
Clinical Pathology
Hematology. No changes in hematology parameters were noted in the 2-wk study. However, hematocrits were slightly lower than pretest, concurrent, and historical controls in 3/4 males and 3/4 females during week 13 in monkeys receiving 44 mg/kg (Table II) . Correspondingly decreased total protein concentrations (see below) suggested blood loss as a cause. The anemia was not regenerative.
Chemistry. Serum urea nitrogen (SUN) and creatinine concentrations obtained during week 2 (2-wk study) or week 13 (13-wk study) are shown in Table III . Corresponding urine osmolality data (13-wk study) are also shown. SUN and/or creatinine concentrations were usually higher than pretest and concurrent control values in all dose groups in the 2-wk study. However, only 1/2 males and 1/2 females receiving 176 mg/kg had SUN concentrations that exceeded the historical control ranges, and only 1/2 males and 1/2 females receiving 88 mg/kg and 1/2 males and 2/2 females receiving 176 mg/kg had creatinine concentrations that exceeded the historical control ranges. Increases were up to 2-fold above the upper limit of the control range. In the 13-wk study, increased SUN concentrations occurred in 1/4 males and 1/4 females during week 4 (data not shown) and in 3/4 males and 1/4 females in week 13. Increased creatinine concentrations occurred in 1/4 males and 1/4 females during week 4 (data not shown) and in 1/4 males in week 13.
The increased SUN and creatinine concentrations were attributed to renal compromise, because the urine osmolality (Table III) was near or below the value considered to indicate appropriate urine concentration during azotemia (54) , and because renal changes were observed microscopically.
Naproxen sodium-related effects on triglyceride and albumin concentrations are shown in Table II . Serum triglyceride concentrations were often higher than pretest values in all monkeys dosed with 176 mg/kg in the 2-wk study, but the values remained within historical control ranges (data not shown). In the 13-wk study, 2/4 males had triglyceride concentrations that were mildly increased during week 13, compared with pretest, concurrent, and historical controls. Albumin concentrations in females receiving 176 mg/kg in the 2-wk study or 44 mg/kg in the 13-wk study were often lower than pretest values, but values remained within historical control ranges (data not shown). However, albumin concentrations were below pretest, concurrent, and historical control values in 2/2 males receiving 176 mg/kg in the 2-wk study and in 4/4 males receiving 44 mg/kg in the 13-wk study. Blood loss was considered to be the most likely cause for the decreased albumin levels. Renal loss of albumin was considered unlikely, as significant proteinuria was not observed in the 13-wk study (urinary protein was not measured in the 2-wk study). Organ Weights After 2 wk of dosing, the absolute and relative renal weights of 1/2 males and 1/2 females were higher than those of weight-matched concurrent and historical controls in the 176 mg/kg dose group (Table IV) . After 13 wk of dosing, the absolute and relative renal weights of 1/4 males and 2/4 females were higher than those of weight-matched concurrent and historical controls in monkeys receiving 44 mg/kg of naproxen sodium. The higher renal weights were attributed to naproxen sodium administration.
Gross Pathology
There were no naproxen sodium-related observations in the 2-wk study. A focal discoloration in the kidney correlating with tubular dilatation was seen in 1/4 male monkeys receiving 44 mg/kg naproxen sodium in the 13wk study.
Microscopic Pathology
A number of naproxen sodium-related renal changes were observed. The incidence and severity of changes were gender independent and are presented in Table V. Renal changes were typically bilateral, although both kidneys were not always equally affected. In the 2-wk study, naproxen sodium-related changes included increased interstitial ground substance, tubular dilatation, and tubulointerstitial nephritis, and the incidence and severity of changes were generally dose related. In addition to the changes observed in the 2-wk study, cortical tubular atrophy and fibrosis were also observed in the 13-wk study.
A &dquo;no effect level&dquo; was not determined. The incidence and severity of increased interstitial ground substance and tubular dilatation was greater in monkeys receiving 44 mg/kg for 13 wk, compared with monkeys receiving up to 176 mg/kg for 2 wk. In contrast, the incidence and severity of tubulointerstitial nephritis in the 13-wk study were similar to those observed in the monkeys receiving 88 mg/kg in the 2-wk study and were less severe than those seen in monkeys receiving 176 mg/kg. Increased interstitial ground substance (10) was typically observed throughout the medulla in both the 2-and 13-wk studies, extending up to the corticomedullary junction and into the medullary rays. In many monkeys, the corticomedullary region was the most severely affected area. The increased interstitial ground substance was TABLE IV.-Changes in renal weightsa in cynomolgus monkeys administered naproxen sodium for 2 or 13 wk.
Abbreviations: M = male; F = female. I Based on combined weight of right and left kidneys. Reference ranges are based on concurrent and historical control data. Abbreviations: M = male; F = female.° In this study, there were 2 monkeys of each gender in each group. b In this study, there were 4 monkeys of each gender in each group. characterized by a blue-gray appearance of the interstitium with H&E stains. Movat's pentachrome staining demonstrated increased blue to blue-green interstitium (Fig. 3A, B ), and the interstitium was slightly to strongly positive with PAS staining. Increased interstitial ground substance was the most prominent microscopic finding in most monkeys, and it occurred in areas with and without tubulointerstitial nephritis. The interstitium separated tubules, sometimes substantially (Figs. 3A, B and 4A). In the 13-wk study, trichrome stains revealed minimal fibrosis in the medullary interstitium and minimal to mild fibrosis in the medullary rays and adjacent cortex (Fig.  3C ). In the 2-wk study, trichrome stains did not reveal any fibrosis. The interstitium in the medulla and medullary rays sometimes contained plump stellate cells, which were consistent with renal interstitial fibroblasts. Some interstitial fibroblasts contained variable numbers of round, clear vacuoles (Fig. 4A ), and others were undergoing necrosis. Mitotic figures were also observed in cells in the interstitium.
Tubular dilatation occurred in kidneys in both studies. In the 2-wk study, tubular dilatation most frequently occurred in the medullary rays and involved the proximal straight tubules, the cortical thick ascending limbs of Henle's loop, and the collecting ducts (Fig. 4B ). Less often, the dilatation involved other cortical and/or medullary tubules. Interestingly, the dilatation in the 2-wk study was most severe in the monkeys receiving 88 mg/ kg. In the 13-wk study, medullary collecting ducts were most often affected (Fig. 4C ), although dilatation also occurred in tubules in the medullary rays and adjacent cortical tissue. Dilated tubules within and adjacent to medullary rays were usually lined by attenuated simple squamous or normal cuboidal epithelium. In contrast, dilated collecting ducts were typically lined by normal cuboidal to slightly hypertrophied and hyperplastic epithelium.
Tubulointerstitial nephritis consisted of inflammatory infiltrates and tubular epithelial changes. Inflammatory infiltrates were scattered throughout the medulla and medullary rays in the 2-wk study and were characterized by multifocal small clusters or scattered individual mixed inflammatory cells in intertubular, intraepithelial, and intratubular locations. In the 13-wk study, the inflammation also involved the cortex adjacent to the medullary rays. The overall severity of the tubulointerstitial nephritis varied from minimal to moderate in the 2-wk study and was dose related, whereas in the 13-wk study, the severity was minimal or mild, and clusters of inflammatory cells were rare. At the 44 mg/kg dose, inflammatory changes were more common and severe in the 13-wk study than in the 2-wk study. Inflammatory cells included neutrophils, mononuclear inflammatory cells (primarily lymphocytes and fewer plasma cells), as well as small numbers of eosinophils (Fig. 4D ). Neutrophils were sometimes observed immediately adjacent to the tubular basement membrane. Mononuclear cells were relatively more common in the 13-wk study than in the 2-wk study. Intratubular inflammatory cells (primarily neutrophils) were often accompanied by smaller numbers of sloughed epithe-lial cells, and these cells occasionally formed casts that filled tubular lumina (Fig. 4E ). Other casts, consisting of amorphous eosinophilic material, were also observed. Casts usually involved only small numbers of tubules in any kidney and were more frequent in the 13-wk study. Medullary collecting ducts, distal thick ascending limbs of Henle's loop, and collecting ducts in medullary rays were most often affected. In some monkeys receiving 88 or 176 mg/kg during the 2-wk study, apparently empty spaces with a crystalline outline (nonbirefringent with polarized light) were infrequently observed in collecting ducts in the medulla. When present, these spaces were always associated with tubular casts, although most casts were not associated with these spaces.
Tubular epithelial changes occurred in both studies and consisted of epithelial attenuation, basophilia, necrosis, hypertrophy, hyperplasia, and karyocytomegaly (necrosis shown in Fig. 4F , hypertrophy and hyperplasia shown in Figs. 3B and 4A, G) . Necrotic tubular epithelial cells were observed infrequently and usually consisted of individual cells or, less frequently, of small clusters of cells in tubular lumina. Sloughed epithelial cells without morphologic features of necrosis were also seen within tubular lumina, usually associated with casts of neutrophils (described above). Sloughed and necrotic epithelial cells were most frequently observed in medullary rays (in proximal straight tubules, distal thick ascending limb of Henle's loop, and collecting ducts), and in collecting ducts in the medulla. Also present were occasional mitotic figures within tubular epithelial cells, especially in the collecting ducts of monkeys from the 13-wk study (Fig. 4G ). The parietal epithelium of Bowman's capsule was sometimes plump, but evidence of glomerular damage was not observed.
Cortical tubular atrophy was observed in the 13-wk study. Distal thick ascending limbs of Henle's loop in medullary rays were primarily affected, although atrophic proximal straight and convoluted tubules were also occasionally observed. Atrophy was often seen in areas of minimal or mild interstitial fibrosis (Fig. 3C ). Atrophic tubules were shrunken and lined by mildly to moderately   FIG. 3. -A) Outer renal medulla from control cynomolgus monkey (2-wk study) demonstrating normal small amounts of yellow-brown interstitium between collecting ducts (with tall cuboidal epithelium and distinct lateral cell borders; 2 shown with *) and tubules of Henle's loop (with low cuboidal epithelium, center and far right). Movat's pentachrome. X225. B) Outer renal medulla from cynomolgus monkey administered 176 mg/kg naproxen sodium for 2 wk. Separation of collecting duct (*) from adjacent tubules of Henle's loop (center and right) by increased blue-green interstitial matrix. Slight hypertrophy and hyperplasia of the epithelium lining the collecting duct are also present. Movat's pentachrome. X225. C) Cross section of medullary ray (center, containing proximal straight tubules, distal thick ascending limbs of Henle's loop, and collecting ducts [one shown with *]) from cynomolgus monkey administered 44 mg/kg naproxen sodium for 13 wk. X400. B) Renal cortex from cynomolgus monkey administered 88 mg/kg naproxen sodium for 2 wk. Tubular dilatation involving proximal straight tubules, distal thick ascending limbs of Henle's loop, and collecting ducts in a medullary ray (1 dilated tubule shown with *). H&E. X45. C) Renal medulla from cynomolgus monkey administered 44 mg/kg naproxen sodium for 13 wk (pelvis in lower left). Prominent tubular dilatation involving collecting ducts. Casts also present in many collecting duct lumina (2 shown with arrowheads).
H&E.
X20. D) Renal cortex from cynomolgus monkey administered 176 mg/kg naproxen sodium for 2 wk. Mixed inflammatory cells in interstitium, including neutrophils, lymphocytes, and plasma cells. H&E. X 300. E) Renal medulla from cynomolgus monkey administered 176 mg/kg naproxen sodium for 2 wk. Cellular cast that includes neutrophils and sloughed epithelial cells in collecting duct. A few neutrophils (arrowhead) also present in interstitium, immediately adjacent to collecting duct. H&E.
X380. F) Renal cortex from cynomolgus monkey administered 88 mg/kg naproxen sodium for 2 wk. Necrosis of epithelial cells (arrowheads) in proximal straight tubule in medullary ray. H&E. X525. G) Renal medulla from cynomolgus monkey administered 44 mg/kg naproxen sodium for 13 wk. Mitotic figures in epithelium of collecting duct (1 shown with arrowhead). Slight hypertrophy and hyperplasia of collecting duct epithelium also present. H&E.
X450. attenuated epithelial cells with amphophilic to slightly basophilic cytoplasm (with H&E staining).
No naproxen sodium-related gastrointestinal changes were observed in either study at necropsy. Microscopic evaluation of gastrointestinal tissues in the 2-wk study also did not reveal any naproxen sodium-related changes. Gastrointestinal tissues were not evaluated microscopically in the 13-wk study.
DISCUSSION
Based on these 2-wk range-finding and 13-wk toxicology studies of naproxen sodium in cynomolgus monkeys, the kidney was identified as the target organ. Because doses of 88 or 176 mg/kg resulted in significant renal toxicity in the 2-wk study while doses of 44 mg/kg were relatively well tolerated, the 13-wk study evaluated only the 44 mg/kg dose. Toxicity was associated with reduced food consumption, body weight loss, renal azotemia, and higher renal weights. Microscopically, naproxen sodium-related renal findings after 2 wk of exposure included increased interstitial ground substance, tubular dilatation, and tubulointerstitial nephritis; fibrosis and cortical tubular atrophy also occurred in the 13-wk study. The incidence and severity of renal changes generally increased with higher doses in the 2-wk study. In the 13-wk study, renal changes were generally of greater incidence and severity compared with those seen in monkeys receiving 44 mg/kg in the 2-wk study. A no effect level was not determined, as renal changes were observed in both studies at the lowest dose tested (44 mg/kg).
The morphologic findings indicate that changes initially occurred in the medulla and medullary rays and then subsequently involved the cortex adjacent to the medullary rays. The increased interstitial ground substance and fibrosis did not appear to be directly related to nephritis, because they occurred in regions lacking inflammatory infiltrates, and because the interstitial changes were more significant in monkeys in the 13-wk study, which had nephritis of lesser severity than monkeys in the 2-wk study. Our findings are consistent with the current view that medullary changes are the primary event in NSAID/analgesic-related renal disease in humans (4, 8, 9, 16, 33, 39) . Findings similar to the increased interstitial ground substance and fibrosis seen in these studies have been observed in humans and laboratory animals that are receiving NSAIDs, other analgesics, or chemicals causing renal papillary necrosis. Increased PAS staining of the medullary interstitium and fibrosis that primarily affects the cortex/medullary ray region have been reported in humans with analgesic nephropathy (8, 9, 26) . Rats administered the papillotoxic chemical 2-bromoethanamine hydrobromide have increased medullary interstitial glycosaminoglycans initially, followed by decreased glycosaminoglycans as the papilla becomes necrotic (3) . Finally, increased interstitial ground substance (hyaluronan, a glycosaminoglycan) occurs in experimental renal graft rejection, associated with interstitial edema (29) . While we did not biochemically evaluate the renal interstitial matrix changes, the staining observed in the monkey kidneys with PAS and Movat's pentachrome is consistent with the reported interstitial ground substance increase and fibrosis that follows various renal injuries.
Renal interstitial fibroblast vacuolation and necrosis were also observed in the monkeys in our studies. Similar interstitial fibroblast alterations have been reported following NSAID administration in humans and laboratory animals (24, 37, 41, 43) . Progressive loss of these cells may be an underlying mechanism involved in NSAIDrelated interstitial changes and renal toxicity, as interstitial fibroblasts appear to be involved in the production of beneficial vasoactive prostaglandins and in the production and modeling of the extracellular matrix, including ground substance (4, 27, 31, 37, 40) . Thus, damage to interstitial fibroblasts could be an underlying cause of the renal changes observed in the monkeys receiving naproxen sodium. Interestingly, we observed occasional mitotic figures in the medullary interstitium. These cells may represent dividing inflammatory cells rather than interstitial fibroblasts, as interstitial fibroblasts are thought to be highly differentiated cells that are unable to replicate (4).
Tubular dilatation was a prominent finding that primarily involved tubules in medullary rays after 2 wk of exposure, or collecting ducts in medullary rays or the medulla after 13 wk of exposure. Physical obstruction of tubules by naproxen crystals (47) or casts of cellular debris (4) have been suggested as causes of tubular dilatation. In the 2-wk study, tubular dilatation was not attributed to physical obstruction by casts and/or crystals, because casts were observed infrequently relative to tubular dilatation, crystalline-like spaces were even more infrequent, and tubular dilatation occurred in kidneys lacking crystals or casts. Instead, the tubular dilatation in the 2wk study was attributed to the interstitial matrix changes leading to tubular compression and obstruction (29) . In contrast, casts were more frequent in the 13-wk study and likely contributed to the tubular dilatation. Tubular atrophy was considered to be secondary to chronic tubular obstruction and fibrosis. Tubular dilatation and atrophy are features of renal disease that are associated with consumption of NSAIDs and other analgesics (4, 5, 7, 9, 12, 23, 24) .
Minimal to mild elevations in SUN and/or creatinine were observed in monkeys receiving naproxen sodium. This azotemia was considered renal in origin and was likely related to the morphologic findings observed in the kidney and/or decreased renal blood flow and glomerular filtration rate. Decreased renal blood flow and glomerular filtration rate have been reported in humans receiving naproxen or other NSAIDs (11, 39, 53) . The lower hematocrit and albumin values were attributed to blood loss, as urinalyses conducted during the 13-wk study revealed no significant proteinuria. Given the known propensity of NSAIDs, including naproxen and naproxen sodium, to induce erosions and ulcers in the gastrointestinal tract, blood loss likely occurred through gastrointestinal microbleeding, despite the lack of naproxen sodium-related findings in the gastrointestinal tract (1, 20, 25, 35, 52) . Unfortunately, tests for fecal occult blood were not performed. The anemia was nonregenerative, possibly secondary to renal disease and decreased erythropoietin pro-duction and/or chronic inflammation (22, 32) . The cause of the elevated triglyceride concentrations was not clear; however, similar elevations occurred following administration of the NSAID L5418 to rhesus monkeys (21) .
Limited pharmacokinetic data were collected in both studies, and they confirmed systemic exposure to naproxen. The Tmax appeared to be earlier than 6 hr, as the naproxen plasma concentrations in the 1and 2-hr samples (from the 2-and 13-wk studies, respectively) were much higher than the 6-hr samples. In comparison, the Tmax in humans following oral administration of naproxen sodium is 40-60 min (46, 48) . AUC values were lower in the 13-wk study compared with the 2-wk study; this may be related to differences in sampling times between the studies. More detailed sampling is needed to definitively determine the pharmacokinetics of naproxen sodium in cynomolgus monkeys. Based on peak plasma concentrations and AUC values, naproxen concentrations increased in a dose-proportional manner between 44 and 88 mg/kg; however, between 88 and 176 mg/kg, the increases were dose related but were less than dose proportional. Similar nonlinear pharmacokinetics have been reported in humans, in which doses above 500 mg, administered twice a day (approximately 15-20 mg/kg/ day), result in a plateau effect with less than dose-proportional increases in plasma concentrations of naproxen (45) . The plateau effect is attributed to saturation of protein binding sites, resulting in more unbound drug that can be cleared by the kidney, and may represent a selfregulatory mechanism that limits plasma levels and thus toxicity (45) .
Overall, the naproxen sodium-related changes observed in monkeys had features similar to (a) the acute renal disease in humans, associated with azotemia; (b) the syndrome associated with acute tubulointerstitial nephritis (although proteinuria was not observed); and, possibly, (c) the syndrome characterized by papillary necrosis (interstitial changes in the kidney medulla may have progressed to necrosis had administration of naproxen sodium been continued). While many of the clinicopathologic and pathologic features of the disease resembled NSAID-associated renal disease in humans, there were some differences. The consistent observation of renal toxicity after 2 wk of administration in the monkeys contrasts with the NSAID-associated nephrotoxicity seen in humans, which is considered to be an uncommon effect in healthy individuals and of highly variable onset; it may occur within days or years after initiation of NSAID therapy (39) . In addition, the syndrome of nephritis in humans may be related to an allergic/immunologic reaction, which may explain the sporadic incidence of the syndrome (5, 23, 39, 50) . Another difference was the nature of the inflammatory infiltrate in the tubulointerstitial nephritis. In most human cases, the infiltrate consists primarily of lymphocytes, although infiltrates that include neutrophils and eosinophils have been described (5, 23, 34, 50) . In contrast, a mixture of neutrophils and mononuclear inflammatory cells were commonly observed in monkeys in both the 2-and 13-wk studies. The differences between humans and monkeys may relate to differences in the timing of evaluations, as human cases are usually restricted to biopsy material obtained in the very early stages of toxic reactions or to autopsy material obtained in the chronic stages of injury. Species differences in the response to NSAIDs are also possible.
The comparative dosages of naproxen/naproxen sodium in rhesus monkeys, humans, and cynomolgus monkeys are interesting in light of the renal toxicity observed in cynomolgus monkeys (information on other nonhuman primates is not available). Renal changes were not described in rhesus monkeys receiving oral controlled-release tablets of naproxen sodium at a dose of 1,500 mg/ day for 7 days (19) or in monkeys (identified as rhesus by R. Hill, personal communication) receiving naproxen orally at doses up to 120 mg/kg/day for 6 mo (28) . However, rhesus monkeys receiving up to 90 mg/kg twice daily for 12 mo developed nephropathy with cortical and papillary changes, although no other details were provided (47) . In humans, the recommended prescription dose of naproxen is 1,000 mg/day divided into 2 doses (15-20 mg/kg/day), although 1,500 mg/day (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) mg/kg/ day) may be used for 2 wk (36, 52) , and 1,800 mg/day of naproxen was administered for 1 mo without any side effects (48) . Thus, on a milligram per kilogram basis, renal toxicity occurs at much lower doses in cynomolgus monkeys than in rhesus monkeys and occurs at doses that are only 2to 3-fold higher than the human prescription dose. Differences in pharmacokinetics, metabolism, and/ or anatomy may play a role in determining toxicity. Our pharmacokinetic data were not sufficient to draw any definitive conclusions regarding species differences. However, anatomical differences are known, as the human kidney is multipyramidal while the cynomolgus monkey kidney is unipyramidal (49) . Furthermore, metabolite differences between rhesus monkeys and humans are known, and they may also exist between cynomolgus monkeys and humans (44, 51) . It is unlikely that the different formulation used in our studies (naproxen sodium vs naproxen, which was used in earlier rhesus studies) would result in the differences in toxicity, as these 2 formulations are very similar in terms of pharmacokinetics, pharmacology, and therapeutic effects at comparable doses (38, 48, 52) .
In summary, the kidney is the target organ following administration of naproxen sodium to cynomolgus monkeys. The consistent development of naproxen sodiumrelated renal toxicity without apparent extrarenal toxicity makes the cynomolgus monkey a potential model with which to explore NSAID-and analgesic-related renal disease.
